The effect of tissue plasminogen activator on retinal bleeding.

Tissue plasminogen activator is a potent thrombolytic agent that recently has been used to treat postvitrectomy fibrin formation. However, a recent report noted anterior and posterior segment bleeding following intracameral tissue plasminogen activator injection. In this study, we performed lensectomy and vitrectomy in 20 rabbits. A retinal blood vessel was incised to stimulate intraocular hemorrhage; bleeding was controlled and vitreous hemorrhage aspirated. Postoperatively, one eye received a 0.1-mL injection of tissue plasminogen activator (25 micrograms); the other received balanced salt solution. The eyes receiving tissue plasminogen activator had a 28% incidence of increased anterior chamber blood and a 61% incidence of increased intravitreal blood. There was no evidence of postinjection bleeding in eyes receiving balanced salt solution. Most cases of bleeding occurred within 24 hours of tissue plasminogen activator injection. Administration of tissue plasminogen activator in the setting of segmented blood vessels may lead to intraocular hemorrhage.

[1]  R. Califf,et al.  Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. , 1988, The American journal of medicine.

[2]  R. Devenyi,et al.  Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. , 1988, Archives of ophthalmology.

[3]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[4]  R. Snyder,et al.  Treatment of experimental intravitreal fibrin with tissue plasminogen activator. , 1987, American journal of ophthalmology.

[5]  R. Snyder,et al.  Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model. , 1987, Archives of ophthalmology.

[6]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[7]  R. Snyder,et al.  Use of tissue plasminogen activator in experimental hyphema. , 1987, Archives of ophthalmology.

[8]  S. D. Bustros,et al.  Thrombin infusion for the control of intraocular bleeding during vitreous surgery. , 1985, Archives of ophthalmology.

[9]  A. Schachat,et al.  Complications of vitreous surgery for diabetic retinopathy. I. Intraoperative complications. , 1983, Ophthalmology.

[10]  Sebestyen Jg Fibrinoid syndrome: a severe complication of vitrectomy surgery in diabetics. , 1982 .

[11]  H. Little Alterations in blood elements in the pathogenesis of diabetic retinopathy. , 1981, Ophthalmology.